The identification of inflammatory fibrosis, sometimes accompanied by granuloma, prompted us to characterize the activity of the JAK/STAT pathway, a potential therapeutic target in both LGL and granulomatosis [20,21]. This evidence concerns the gene SOAT1 and Granuloma.